sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Company profile
Ticker
SRPT
Exchange
Website
CEO
Douglas Ingram
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANTIVIRALS INC, AVI BIOPHARMA INC
SEC CIK
Corporate docs
Subsidiaries
Sarepta Securities Corp. • ST International Holdings • Sarepta Therapeutics Three, LLC ...
IRS number
930797222
SRPT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Feb 24
8-K
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
8 Jan 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
S-8
Registration of securities for employees
2 Aug 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Regulation FD Disclosure
22 Jun 23
8-K
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
22 Jun 23
8-K
Departure of Directors or Certain Officers
9 Jun 23
10-Q
2023 Q1
Quarterly report
2 May 23
DEFA14A
Additional proxy soliciting materials
24 Apr 23
Transcripts
SRPT
Earnings call transcript
2023 Q4
28 Feb 24
SRPT
Earnings call transcript
2023 Q3
1 Nov 23
SRPT
Earnings call transcript
2023 Q2
2 Aug 23
SRPT
Earnings call transcript
2023 Q1
2 May 23
SRPT
Earnings call transcript
2022 Q4
28 Feb 23
SRPT
Earnings call transcript
2022 Q3
3 Nov 22
SRPT
Earnings call transcript
2022 Q2
2 Aug 22
SRPT
Earnings call transcript
2022 Q1
5 May 22
SRPT
Earnings call transcript
2021 Q4
2 Mar 22
SRPT
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
4
Hans Lennart Rudolf Wigzell
11 Mar 24
4
Bilal Arif
11 Mar 24
4
Louise Rodino-Klapac
11 Mar 24
4
Kathryn Jean Boor
11 Mar 24
4
Ryan Edward Brown
11 Mar 24
4
Ian Michael Estepan
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
Ian Michael Estepan
6 Mar 24
4
Stephen Mayo
6 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 561.08 mm | 561.08 mm | 561.08 mm | 561.08 mm | 561.08 mm | 561.08 mm |
Cash burn (monthly) | 103.29 mm | 41.38 mm | 11.06 mm | 65.52 mm | 38.24 mm | 44.89 mm |
Cash used (since last report) | 614.08 mm | 246.01 mm | 65.74 mm | 389.52 mm | 227.31 mm | 266.90 mm |
Cash remaining | -52.99 mm | 315.07 mm | 495.34 mm | 171.56 mm | 333.77 mm | 294.18 mm |
Runway (months of cash) | -0.5 | 7.6 | 44.8 | 2.6 | 8.7 | 6.6 |
Institutional ownership, Q3 2023
88.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 395 |
Opened positions | 49 |
Closed positions | 59 |
Increased positions | 152 |
Reduced positions | 122 |
13F shares | Current |
---|---|
Total value | 9.89 tn |
Total shares | 82.62 mm |
Total puts | 3.09 mm |
Total calls | 3.83 mm |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 8.57 mm | $1.04 tn |
BLK Blackrock | 6.03 mm | $731.41 bn |
JHG Janus Henderson | 5.78 mm | $700.94 bn |
JPM JPMorgan Chase & Co. | 4.61 mm | $558.62 bn |
Avoro Capital Advisors | 4.03 mm | $487.91 bn |
Wellington Management | 3.91 mm | $473.95 bn |
BK Bank Of New York Mellon | 2.51 mm | $304.43 bn |
STT State Street | 1.99 mm | $240.69 bn |
FMR | 1.91 mm | $231.68 bn |
T. Rowe Price Investment Management | 1.90 mm | $229.35 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Kathryn Jean Boor | Common Stock | Sell | Dispose S | No | No | 122.93 | 761 | 93.55 k | 7,516 |
8 Mar 24 | Hans Lennart Rudolf Wigzell | Common Stock | Sell | Dispose S | No | No | 122.39 | 100 | 12.24 k | 22,840 |
8 Mar 24 | Hans Lennart Rudolf Wigzell | Common Stock | Sell | Dispose S | No | No | 123.1 | 11,745 | 1.45 mm | 22,940 |
8 Mar 24 | Hans Lennart Rudolf Wigzell | Common Stock | Sell | Dispose S | No | No | 123.85 | 3,155 | 390.75 k | 34,685 |
8 Mar 24 | Hans Lennart Rudolf Wigzell | Common Stock | Option exercise | Acquire M | No | No | 13.9 | 15,000 | 208.50 k | 37,840 |
8 Mar 24 | Hans Lennart Rudolf Wigzell | Stock Option Common Stock | Option exercise | Dispose M | No | No | 13.9 | 15,000 | 208.50 k | 0 |
8 Mar 24 | Bilal Arif | Common Stock | Payment of exercise | Dispose F | No | No | 123.14 | 472 | 58.12 k | 25,222 |
8 Mar 24 | Louise Rodino-Klapac | Common Stock | Payment of exercise | Dispose F | No | No | 123.14 | 909 | 111.93 k | 68,073 |
8 Mar 24 | Ryan Edward Brown | Common Stock | Payment of exercise | Dispose F | No | No | 123.14 | 899 | 110.70 k | 28,688 |
7 Mar 24 | Bilal Arif | Common Stock | Payment of exercise | Dispose F | No | No | 120.49 | 506 | 60.97 k | 25,694 |
News
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
8 Mar 24
UBS Maintains Buy on Sarepta Therapeutics, Raises Price Target to $167
1 Mar 24
Cantor Fitzgerald Reiterates Neutral on Sarepta Therapeutics, Maintains $128 Price Target
29 Feb 24
RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $157
29 Feb 24
Citigroup Maintains Buy on Sarepta Therapeutics, Raises Price Target to $172
29 Feb 24
Press releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Feb 24
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
21 Feb 24
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
16 Feb 24
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Jan 24
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
16 Jan 24